metricas
covid
Buscar en
Vacunas (English Edition)
Toda la web
Inicio Vacunas (English Edition) Immuno-informatics design of a multimeric epitope peptide-based vaccine against ...
Journal Information
Vol. 24. Issue 4.
Pages 380-393 (October - December 2023)
Share
Share
Download PDF
More article options
Visits
556
Vol. 24. Issue 4.
Pages 380-393 (October - December 2023)
Original Article
Immuno-informatics design of a multimeric epitope peptide-based vaccine against dengue virus serotype-2
Diseño inmunoinformático de una vacuna basada en péptidos epítopos multiméricos contra el virus del dengue serotipo-2
Visits
556
Mohamed Sheik Tharik Abdul Azeezea,1,
Corresponding author
, Rajaguru Arivuselvamb,1
a Department of Pharmaceutical Analysis, College of Pharmacy, JSS Academy of Technical Education, Noida, Uttar Pradesh, India
b Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagar, Mysore, KA, India
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (19)
Show moreShow less
Tables (7)
Table 1. Evaluation of physicochemical properties of DENV EP, Halobacteriumsalinarum and Vaccine candidate.
Table 2. Detailed analysis of CD8+& CD4+ epitope.
Table 3. Detailed analysis of Linear B- cell epitope.
Table 4. Tertiary structure perdition of designed vaccine by RaptorX structure prediction server.
Table 5. Refinement of constructed vaccine.
Table 6. It represents conformation of linear B- cell epitope.
Table 7. It represents binding affinity between our construted vaccine and TLR2, TLR7.
Show moreShow less
Abstract
Introduction

Dengue viral infection affects approximately 130 countries worldwide. According to WHO reports, 40% of the global population lives in rural areas with a high risk of contracting dengue. Researchers have identified four distant strains of the dengue virus, and a single vaccine has not permanently controlled the emergence of all four distant strains. Therefore, a vaccine is required for each of the four strains to address the current situation.

Objectives

The objective of this study was to design a multi-epitope-based vaccine for the dengue virus-2 strain that elicits a robust immune response while being safe and non-allergenic.

Results

Firstly, we analyzed the envelope protein for its physicochemical and antigenic properties. Next, we predicted MHC I, MHC II, and B-cell epitopes with high accuracy and evaluated their properties. Then, we constructed a vaccine using a suitable adjuvant and linkers, and predicted the secondary and tertiary structure of the vaccine, and the tertiary structure was validated. After conducting molecular docking with toll-like receptors, we utilized the best-docked result for molecular stimulation. Finally, we analyzed the immune stimulation against the vaccine, and the results showed positive immune responses from macrophages, DC cells, T-cells, and B-cells. Additionally, we found that the vaccine was excreted from the human body.

Conclusions

Our study demonstrates the potential of using immunoinformatic tools and immunological knowledge to design a multi-epitope-based vaccine for the dengue virus-2 strain. This approach could be applied to designing vaccines for other diseases, and further studies are required to validate its effectiveness in vivo.

Keywords:
Dengue virus-2
Immunoinformatics
Vaccine linkers
In-silico biology
Epitope
Immunization
Resumen
Introducción

La infección viral por dengue afecta aproximadamente a 130 países a nivel mundial. Según informes de la OMS, el 40% de la población mundial vive en zonas rurales con alto riesgo de contraer dengue. Los investigadores han identificado cuatro cepas distantes del virus del dengue y una sola vacuna no ha controlado permanentemente la aparición de las cuatro cepas distantes. Por lo tanto, se requiere una vacuna para cada una de las cuatro cepas para hacer frente a la situación actual.

Objetivos

El objetivo de este estudio fue diseñar una vacuna basada en múltiples epítopos para la cepa del virus del dengue-2 que provoque una respuesta inmunitaria robusta a la vez que sea segura y no alergénica.

Resultados

En primer lugar, analizamos la proteína de la envoltura en cuanto a sus propiedades fisicoquímicas y antigénicas. A continuación, predijimos epítopos de MHC I, MHC II y células B con gran precisión y evaluamos sus propiedades. Luego, construimos una vacuna utilizando un adyuvante y enlazadores adecuados, y predijimos la estructura secundaria y terciaria de la vacuna, y se validó la estructura terciaria. Después de realizar el acoplamiento molecular con receptores tipo toll, utilizamos el mejor resultado acoplado para la estimulación molecular. Finalmente, analizamos la estimulación inmunológica contra la vacuna y los resultados mostraron respuestas inmunológicas positivas de macrófagos, células DC, células T y células B. Además, encontramos que la vacuna se excretaba del cuerpo humano.

Conclusiones

Nuestro estudio demuestra el potencial del uso de herramientas inmunoinformáticas y conocimiento inmunológico para diseñar una vacuna basada en múltiples epítopos para la cepa del virus del dengue-2. Este enfoque podría aplicarse al diseño de vacunas para otras enfermedades, y se requieren más estudios para validar su eficacia in vivo.

Palabras clave:
Dengue virus-2
Inmunoinformática
Enlazadores de vacunas
Biología in-silico
Epítopo
Inmunización

Article

These are the options to access the full texts of the publication Vacunas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Vacunas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.vacune.2022.11.004
No mostrar más